[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100442909":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":20,"interventions":27,"overallOfficials":13,"centralContacts":33,"locations":39,"responsibleParty":62,"collaborators":13,"id":66,"slug":13,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":13,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":13,"studyType":79,"phases":80,"briefSummary":81,"conditions":82,"keywords":13,"overallStatus":42,"whyStopped":13,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Chinese Academy of Sciences","OTHER_GOV",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"HCC lesions","Numbers of intraoperatively detected hepatocellular carcinoma lesions.","During hepatocellular resection surgery.",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"NA","SINGLE_GROUP","DIAGNOSTIC",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE",[21],{"label":22,"type":23,"description":24,"interventionNames":25},"Anti-GPC3-IRDye800CW Intraoperative Fluorescence","EXPERIMENTAL","The patients will receive an injection of fluorophore (Anti-GPC3-IRDye800CW) before the surgery. Then intraoperative fluorescence imaging will be performed to guide lesion resection.",[26],"Drug: Anti-GPC3-IRDye800CW",[28],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":13},"DRUG","Anti-GPC3-IRDye800CW","Drug Injection: Anti-GPC3-IRDye800CW",[22],[34],{"name":35,"role":36,"phone":37,"phoneExt":13,"email":38},"Zeyu Zhang, Ph.D.","CONTACT","86-18201082715","zhangzeyu@fingerpass.net.cn",[40,53],{"facility":41,"status":42,"city":43,"state":44,"zip":13,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":13},"Zhuhai People's Hospital","RECRUITING","Zhuhai","Guangdong","China","CN",{"type":48,"coordinates":49},"Point",[50,51],113.56778,22.27694,{"lat":51,"lon":50},{"facility":54,"status":42,"city":55,"state":56,"zip":13,"country":45,"countryCode":46,"cosmosGeoPoint":57,"geoPoint":61,"contacts":13},"The Affiliated Hospital of Southwest Medical University","Luzhou","Sichuan",{"type":48,"coordinates":58},[59,60],105.42575,28.8903,{"lat":60,"lon":59},{"type":63,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":13,"oldOrganization":13},"PRINCIPAL_INVESTIGATOR","Zeyu Zhang, PHD","Principal Investigator","100442909",false,"NCT05047510","GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma","An Evaluation Study of GPC3 Targeted Fluorescence Imaging to Guide the Surgery of Hepatocellular Carcinoma","Inclusion Criteria:\n\n1. Patients who have been diagnosed with hepatocellular carcinoma.\n2. Planned to receive hepatectomy.\n3. Liver function Child-Pugh A\u002FB.\n4. GPC-3 was validated highly expressed preoperatively.\n5. Aged 18 to 75, and the expected lifetime is longer than 6 months.\n6. Approved to sign the informed consent.\n\nExclusion Criteria:\n\n1. Allergic to IRDye800.\n2. Enrolled in other trials in the past 3 months.\n3. Another malignant tumor was found.\n4. Undesirable function of heart, lung, kidney, or any other organs.\n5. Unable to tolerate a hepatectomy.\n6. The researchers considered inappropriate to be included.",true,"ALL","18 Years","75 Years",{"count":77,"type":78},60,"ESTIMATED","INTERVENTIONAL",[15],"This study is to evaluate whether intraoperative fluorescence imaging targeting GPC3 can aid improve the surgical accuracy of hepatocellular carcinoma.\n\nThe main purposes of this study include:\n\n① To raise the detection rate of hepatocellular carcinoma intraoperatively using the novel NIR-II fluorescence molecular imaging and the GPC-3 targeted fluorophore.\n\n② To validate the safety and effectiveness of the designed GPC-3 targeted fluorophore for clinical application.",[83],"Hepatocellular Carcinoma","2023-08-28",{"date":86,"type":87},"2023-08-30","ACTUAL",{"date":89,"type":87},"2021-09-10",{"date":91,"type":78},"2026-12-31",{"name":5,"class":6},2]